Treatments of Striae Gravidarum
Conditions
Keywords
Striae Gravidarum, Fractional Laser, Platelet-Rich Plasma (PRP), Nanofat Graft, Combination Therapy
Brief summary
Nowadays, multiple treatment modalities have been applied clinically to treat striae gravidarum, such as laser therapy, microdermabrasion, platelet-rich plasma injection(PRP), etc. To some extent, these treatments can improve striae gravidarum. In this clinical trial, the investigators are going to treat striae gravidarum by using two different kinds of combination therapies. One is fractional laser and PRP injection synergy, and the other one is treated by nanofat grafting with PRP injection.
Detailed description
The investigators will pick out two areas of most severe striae gravidarum on a participant's abdomen. One of the areas will be treated by fractional laser once every three months for 2 times combined with PRP injection once a month for 6 times. Another area will be treated by nanofat grafting once every three months for 2 times and PRP therapy once a month for 6 times. The participants were asked to come back 1、3、6、9 months after treatment for further follow-up. Before and after the treatment, the striae gravidarum will be assessed subjectively by satisfaction assessment, dermatoscope and ultrasound, and objectively by immunohistochemical analysis.
Interventions
DEVICEFractional CO2 Laser
Fractional Carbon Dioxide Laser will be treated once every three months for 2 times.
PROCEDURENanofat grafting
Nanofat grafting will be applied once every three months for 2 times.
PROCEDUREPlatelet-rich plasma (PRP) Injection
PRP Injection will be applied once a month for 6 times.
Sponsors
Science and Technology Program of Guangzhou
First Affiliated Hospital of Jinan University
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
No minimum to 35 Years
Healthy volunteers
No
Inclusion criteria
* The striae gravidarum was appeared within 3 years * Age ≤ 35 years old * Not in lactation * Not pregnancy within one year
Exclusion criteria
* Skin allergy * Skin inflammation or wound * Platelet dysfunction syndrome * Take anticoagulant drugs * Acute or chronic infection * Chronic liver disease * Photodermatosis * Active vitiligo, psoriasis, systemic lupus erythematosus * Other clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunohistochemical analysis | Baseline and 15 months. | The tissue extracted will be taken for immunohistochemical analysis to observe the change of epidermal and dermal thickness, and the distribution and amount of elastic fiber and collagen fiber,etc. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dermatoscope | Baseline and at 3,6,9,12,15 months after the treatments. | The striae gravidarum will be assessed by dermatoscope to observe the pigmentation condition of striae after the application of laser or nanofat grafting with PRP injection. |
| Ultrasound | Baseline and at 3,6,9,12,15 months after the treatments. | The striae gravidarum will be assessed by ultrasound in order to observe the change of dermal thickness of striae after the application of laser or nanofat grafting with PRP injection. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Satisfaction assessments | After every sessions of treatments, and at 6,9,12,15 months. | The participants, investigators and physicians will fill in a satisfaction assessment about any complication during the treatments. |
Countries
China
Outcome results
None listed